Please set your featured image
Midatech Pharma: New research collaboration and promising results for new eye disease drug
Midatech Pharma has signed a new research collaboration with Dana-Farber Cancer Institute (Dana Farber), to test the preclinical effectiveness of Midatech’s targeted nanomedicines against Glioblastoma (a type of brain cancer). Dana Farber ia a principal teaching affiliate of Harvard Medical School, Boston, Massachusetts, one of the US’s premier cancer centers. Read the full report at Interactive Investor.
In addition CEO Jim Phillips, in conversation today with Proactive Investor, revealed that eye-disease drug OpsiSporin is on an accelerated programme in terms of investment priorities after it showed ‘exceedingly good promise’ with the company’s controlled release technology.
Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. Headquartered in Abingdon, the company also has an R&D base at Begbroke Science Park. For more information about Midatech visit their website.